Avoid common mistakes on your manuscript.
Dear Editor,
Low cardiac output syndrome (LCOS) affects approximately 25% of children undergoing open heart surgery (OHS) and is associated with increased morbidity and mortality [1]. Evidence for preventive drug therapy for LCOS is derived primarily from the PRIMACORP study [1], which reported a reduction in LCOS risk after administration of high-dose milrinone, using a bolus of 75 μg/kg, followed by a maintenance infusion of 0.75 μg kg−1 min−1 over 35 h. Low-dose milrinone (25 μg/kg bolus and 0.25 μg kg−1 min−1 infusion) was not more effective than placebo. Other drugs may be also used but are not supported by safety and efficacy data [2, 3]. Data on drug use for LCOS prevention in children with OHS is not available for Europe. Therefore, the aim of this study was to characterise hospital practices related to preventive drug therapy for LCOS in children undergoing OHS as a basis for improving the standard of care in this setting.
A Web-based questionnaire was developed to survey 125 specialised hospitals from 36 European countries between January and August 2009. It included 15 questions allocated to 4 sections: prescribing resources and LCOS treatment (data not shown), LCOS prevention, and participant characteristics and comments. The questions on LCOS prevention enquired about the target patient group (all, at risk, none) and mode of drug administration, which was not further stratified. The hospitals were notified by email; of those, 90 hospitals from 31 countries responded (72.0% response rate). Respondents included clinicians (98.9%) and pharmacists (1.1%), specialising primarily in paediatric intensive care, anaesthesiology, cardiology, and cardiothoracic surgery. Nearly all respondents (94.4%) had at least 5 years of experience in caring for children undergoing OHS.
Most European hospitals (70 out of 90) reported preventive drug therapy for LCOS, from which the majority (57 hospitals) selectively targeted patients at risk. However, the drug use was highly variable. In total, 24 different drug regimens were reported, including 17 drugs from 7 therapeutic drug classes. Overall, 70.7% of the drug regimen reports included milrinone, making this the most commonly used drug. Dopamine, dobutamine, epinephrine, and levosimendan were reported significantly less often (Table 1). The dosage and duration of drug administration differed substantially among hospitals.
The results of this survey present the current pattern of drug use for LCOS prevention in children with OHS across Europe, which is characterised by a marked variability. In addition, the dose of milrinone appears to be lower than that supported by PRIMACORP. Although our survey shows that milrinone is the most frequently used drug in Europe, neither the dosing nor the duration of drug administration coincide with those demonstrating efficacy in PRIMACORP (Table 1). Reasons for the reduced dose of milrinone may be attributable to concerns about potential side effects, especially hypotension [4], and the role of age-specific pharmacokinetic differences in the elimination of milrinone [5]. Nonetheless, these factors cannot explain the generally lower dose of milrinone used across all paediatric age groups, which needs to be addressed in future clinical research.
In summary, preventive drug therapy for LCOS in children undergoing OHS is highly variable across Europe, and the data available to support current hospital practices are insufficient. Given the importance of balancing benefits and risks with preventive drug therapy, this survey emphasises the need for further studies that will substantiate effective and safe LCOS prevention.
References
Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, Bailey JM, Akbary A, Kocsis JF, Kaczmarek R, Spray TL, Wessel DL (2003) Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107:996–1002
Baldasso E, Garcia PCR, Piva JP, Branco RG, Tasker RC (2009) Pilot safety study of low-dose vasopressin in non-septic critically ill children. Intensive Care Med 35:355–359
Pasquali SK, Hall M, Li JS, Peterson ED, Jaggers J, Lodge AJ, Marino BS, Goodman DM, Shah SS (2010) Corticosteroids and outcome in children undergoing congenital heart surgery: analysis of the Pediatric Health Information Systems database. Circulation 122:2123–2130
Brierley J, Peters M (2006) Hemodynamics of milrinone loading in critically ill children. Crit Care Med 34:A63
Bailey JM, Hoffman TM, Wessel DL, Nelson DP, Atz AM, Chang AC, Kulik TJ, Spray TL, Akbary A, Miller RP, Wernovsky G (2004) A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J Pharmacokinet Pharmacodyn 31:43–59
Acknowledgments
The results presented in this Letter to the Editor are part of the PhD work of Ms Vogt, carried out at Heinrich Heine University of Düsseldorf. The authors would like to thank all of the members of the expert panel in the field of paediatric cardiology, anaesthesiology, intensive care, cardiac surgery, general medicine, and psychology for their support during the questionnaire development, the survey participants for taking the time to complete the questionnaire, and the European Congenital Heart Disease Organisation members for establishing contact with various hospitals. We would also like to thank Dr. Lechner for review and comments on the manuscript.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Vogt, W., Läer, S. Drug use patterns for the prevention of paediatric low cardiac output syndrome in Europe. Intensive Care Med 37, 1390–1391 (2011). https://doi.org/10.1007/s00134-011-2266-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-011-2266-5